Advertisement

Topics

Poxel reports positive results from PXL770 phase 1b MAD trial and drug─drug interaction study

15:53 EDT 19 Jul 2018 | PharmaBiz

POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non─alcoholic steatohepatitis (NASH), has announced favorable

Original Article: Poxel reports positive results from PXL770 phase 1b MAD trial and drug─drug interaction study

NEXT ARTICLE

More From BioPortfolio on "Poxel reports positive results from PXL770 phase 1b MAD trial and drug─drug interaction study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...